All In Biotech

Drug Trial Radar · NCT02750306

Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)

A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Oct 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 285 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

285

Actual

Start

May 23, 2016

Primary completion

Sep 30, 2018

Study completion Sep 30, 2018

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to examine the safety and efficacy of suvorexant (MK-4305) to improve sleep in individuals with Alzheimer's disease (AD). The primary hypothesis for the study is that suvorexant is superior to placebo in improving insomnia as measured by change from baseline in polysomnography (PSG)-derived total sleep time (TST) at Week 4.

Conditions

  • Sleep Initiation and Maintenance Disorders
  • Alzheimer Disease

Interventions

  • SuvorexantDrug

    10 mg tablet (may be increased to 20 mg tablet)

  • PlaceboDrug

    Placebo to suvorexant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Polysomnography-derived Total Sleep Time (TST) at Week 4Time frame: Baseline and Week 4
  2. Percentage of Participants Who Experienced One or More Adverse EventsTime frame: Up to 6 weeks
  3. Percentage of Participants Who Discontinued Study Drug Due to an Adverse EventTime frame: Up to 4 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.